COPD without smoking? New data reveal unexpected symptoms and inflammation patterns. Read more to see what this means for ...

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...

(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

If you're experiencing cold or flu-like symptoms this winter – your symptoms may be linked to a lesser-known respiratory ...

Patients with respiratory conditions, such as asthma and COPD, are being encouraged to use apps to manage their symptoms.

For women over 40, certain common symptoms could be signs of an underlying health condition. Learn more about what to watch for.

Healthcare providers have called on the government to ensure that there is proper education of Nigerian citizens about asthma and Chronic Obstructive Pulmonary Disease (COPD), as well as improved ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...